31 / 34
31
16.
World Health Organization. Assessment of fracture risk
and its application to screening for postmenopausal
osteoporosis. Geneva, Switzerland: WHO; 1994.
17.
Zehnder Y, Risi S, Michel D, Knecth H, Perrelet R, et al.
Prevention of bone loss in paraplegics over 2 years with
alendronate. J Bone Mineral Res 2004;19:1067-74.
18.
Moran de Brito CM, Batistella LR, Saito ET, Sakamoto H.
Effect of alendronate on boné mineral density in spinal
cord injury patients: a pilot study. Spinal Cord
2005;43:341-8.
19.
Bubbear JS, Gall A, Middleton FRI, Fergunson-Pell M,
Swaminathan R, Keen RW. Early treatment with
zoledronic acid prevents bone loss at the hip following
acute spinal cord injury. Osteoporosis 2011;22:271-9.
20.
Minaire P, Depassio J, Berard E, Meunier PJ, Edouard C,
Pilonchery G, et al. Effects of clodronate on
immobilization bone loss. Bone 1987;8 Suppl 1:S63-8.
21.
Pearson EG, Nance PW, Leslie WD, Ludwig S. Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury.Arch Phys Med Rehabil
1997;78:269-72.
22.
Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J,
Uebelhart D. Intravenous pamidronate attenuates bone
density loss after acute spinal cord injury. Arch Phys
Med Rehabil 1999;80:243-51.
23.
Bauman WA,Wecht JM,
Kirshblum S, Spungen AM, Morrison N, Cirnigliaro C,
et al.
Effect of pamidronate administration on bone in patients with acute spinal cord injury.J Rehabil Res Dev 2005;42:305-13.
24.
Chappard D,Minaire P, Privat C, Berard E, Mendoza- Sarmiento J, Tournebise H,
et al,
Effects of tiludronate on bone loss in paraplegic patients.J Bone Miner Res
1995;10:112-8.